More than 150 Middle East urologists attended the annual European Urological Association (EUA) meeting recently in Paris, where global pharmaceutical company, Pfizer, shared important new data from a recently concluded clinical study which included participants from Arabian Gulf and North African countries.
An annual event now in its twenty-first year, the EUA is considered to be one of the world’s top gatherings of urologists, with more than 12,000 in attendance.
Pfizer used the occasion to demonstrate the significant correlation between patients successfully treated for erectile dysfunction (ED) with Viagra and increased self-esteem.
“The new data presented at EUA confirms our belief, as urologists who treat ED sufferers, that treatment with Viagra better enables doctors to set treatment goals that lead to measurable patient improvement,” said Dr. Abdul Qadir I. Al Zarouni, a UAE-based urologist who attended the annual meeting.
“The most interesting finding was that erection quality was measured by respondents in terms of rigidity, and that measurement directly correlated with patient satisfaction and self-esteem, particularly in Middle East participants in the study,” added Zarouni.
Discovered and developed by Pfizer, Viagra is a breakthrough oral treatment for erectile dysfunction that has been found to be effective and well-tolerated in more than 130 clinical studies. The drug is prescribed in over 120 countries, and more than 27 million men worldwide have benefited from its therapy.
